Asperosaponin VI suppresses ferroptosis in chondrocytes and ameliorates osteoarthritis by modulating the Nrf2/GPX4/HO-1 signaling pathway
Frontiers in Pharmacology · 28.02.2025 · 16
DOI: 10.3389/fphar.2025.1539092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.02.2025. Verfasst von Zhimeng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical and Health Science and Technology Development Project of Shandong Province.
Abstract (Originalsprache)
Background
Asperosaponin VI (AVI) is a naturally occurring monosaccharide derived from Dipsacus asperoides renowned for its anti-inflammatory and bone-protective properties.
Objective
To elucidate the specific mechanism through which AVI affects chondrocytes in osteoarthritis (OA).
Methods
For the in vitro experiments, primary chondrocytes were to elucidate the molecular mechanisms underlying the action of AVI.For the in vivo experiments, rat OA models were established using a modified Hulth method. The severity of knee osteoarthritis was evaluated 8 weeks post-surgery. Micro-CT imaging, hematoxylin-eosin staining, and Safranin O-fast green staining were used to assess degeneration in rat knee joints. Immunohistochemistry techniques were conducted to measure the levels of collagen II, MMP13, Nrf2, GPX4, ACSL4, and HO-1 within cartilage tissues. ELISA assays were performed to measure those of TNF-α, IL -6, and PGE2 in serum samples.
Results
AVI alleviated chondrocyte apoptosis and extracellular matrix degradation in rat OA induced by IL-1β. It attenuated the levels of TNF-α, IL-6, and PGE2 while reducing those of Fe 2+ and malondialdehyde (MDA). AVI upregulated the expression of Nrf2, HO-1, and GPX4 while downregulating that of ACSL4. Mechanistic studies revealed that ML385-induced inhibition of the Nrf2 signaling pathway reversed the increase in GPX4 and ACSL4 expression and increased Fe 2+ and MDA levels; treatment with erastin, a ferroptosis inducer, produced comparable results. In vivo experiments demonstrated that AVI improved the bone volume/tissue volume and trabecular separation values in OA rats; reversed the Osteoarthritis Research Society International score; upregulated Nrf2, HO-1, and GPX4 expression; downregulated ACSL4 and MMP13 expression, and decreased the serum levels of TNF-α, IL-6, and PGE2.
Conclusion
Our findings suggest that AVI is a promising therapeutic agent for OA. It exerted its protective effect by regulating the Nrf2/GPX4/HO-1 signaling axis to inhibit cartilage cell ferroptosis and improve osteoarthritis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- First Clinical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
- Department of Orthopedic Surgery, Affliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Förderung
- National Natural Science Foundation of China
- Medical and Health Science and Technology Development Project of Shandong Province
Zitieren
APA
Zhang, Z., Yuan, D., Jin, X., Chang, W., Zhang, Y., & Xie, W. (2025). Asperosaponin VI suppresses ferroptosis in chondrocytes and ameliorates osteoarthritis by modulating the Nrf2/GPX4/HO-1 signaling pathway. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1539092
Vancouver
Zhang Z, Yuan D, Jin X, Chang W, Zhang Y, Xie W. Asperosaponin VI suppresses ferroptosis in chondrocytes and ameliorates osteoarthritis by modulating the Nrf2/GPX4/HO-1 signaling pathway. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1539092
BibTeX
@article{Zhang2025,
author = {Zhang, Zhimeng and Yuan, Daotong and Jin, Ximin and Chang, Wenjie and Zhang, Yongkui and Xie, Wenpeng},
title = {Asperosaponin VI suppresses ferroptosis in chondrocytes and ameliorates osteoarthritis by modulating the Nrf2/GPX4/HO-1 signaling pathway},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1539092}
}
EUVIMED